- Home
- Publications
- Publication Search
- Publication Details
Title
Ramucirumab: A Review in Hepatocellular Carcinoma
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 3, Pages 315-322
Publisher
Springer Science and Business Media LLC
Online
2020-02-07
DOI
10.1007/s40265-020-01263-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) A Vogel et al. ANNALS OF ONCOLOGY
- Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
- (2019) Teiji Kuzuya et al. HEPATOLOGY RESEARCH
- Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).
- (2019) Josep M Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
- (2019) Peter Galle et al. JOURNAL OF HEPATOLOGY
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
- (2019) Robert Montal et al. BRITISH JOURNAL OF CANCER
- Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
- (2019) Peter R. Galle et al. LIVER INTERNATIONAL
- 757PEfficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
- (2019) M Kudo et al. ANNALS OF ONCOLOGY
- 753PPrognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
- (2019) A X Zhu et al. ANNALS OF ONCOLOGY
- 758PRamucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis
- (2019) J Llovet et al. ANNALS OF ONCOLOGY
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- 149OEfficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies
- (2018) Y-K Kang et al. ANNALS OF ONCOLOGY
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
- (2017) Masao Omata et al. Hepatology International
- A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors
- (2017) Hiroshi Nokihara et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
- (2017) Junning Cao et al. ONCOLOGIST
- Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region
- (2016) Ran Xu Zhu et al. Gut and Liver
- Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
- (2015) E. G. Chiorean et al. ANNALS OF ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now